A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Recruiting · NCT05341557 · Registry updated 2025-01-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hepatocellular carcinoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-small cell lung carcinoma | Recruiting | Phase 1 | 2025-01-27 | NCT05341557 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Betta Pharmaceuticals Co., Ltd. | 20 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Chaoyang | China | 1 |
| Cangzhou Central Hospital | Cangzhou | China | 1 |
| Tianjin Cancer Hospital | Tianjin | China | 24 |
| Tianjin Medical University General Hospital | Tianjin | China | 4 |